An overactive stress response contributes to the development of insulin resistance in obese individuals, and blocking it may be therapeutically beneficial.
Vanderbilt researchers have discovered that certain immune cells contribute to the development of hypertension, suggesting novel targets for treating the disease.
Clinical pharmacologist Jens Titze, M.D., and his colleagues have identified a new cast of cells and molecules that function in the skin to control sodium balance and blood pressure.
Cheryl Laffer, M.D., PhD., professor of Medicine, is the new director of the Hypertension Service within the Division of Clinical Pharmacology.
A newer version of an old class of blood pressure lowering drugs may offer advantages for obese patients with metabolic syndrome.
Accessibility Tools